Key result
Ramipril and valsartan increased plasma adiponectin levels significantly more than other antihypertensive regimens (P<0.05 for both).
Why the study?
Do different antihypertensive agents improve plasma adiponectin levels in hypertensive patients with metabolic syndrome?
Do different antihypertensive agents improve plasma adiponectin levels in hypertensive patients with metabolic syndrome?
p-value: p=<0.05
In hypertensive patients with metabolic syndrome, treatment with ramipril or valsartan significantly increases plasma adiponectin levels compared to other antihypertensive agents.
No takes yet. Share an insight, caveat, or question.
Ramipril and valsartan were associated with greater adiponectin increases than alternatives; leaves open clinical relevance in metabolic syndrome hypertension.
Yılmaz et al. (2007) studied Hypertension with metabolic syndrome (n=96). Antihypertensive agents (ramipril, valsartan, metoprolol, amlodipine, doxazosin) vs. Compared among regimens was evaluated on Plasma adiponectin levels (p=<0.05). Ramipril and valsartan increased plasma adiponectin levels significantly more than other antihypertensive regimens (P<0.05 for both).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: